Melanotan II — Broad-Spectrum α-MSH Analogue

Discovery and origins at the University of Arizona

Melanotan II was developed during a sustained programme of melanotropic peptide research conducted at the University of Arizona from the late 1970s through the 1990s. The principal investigators — pharmacologist Mac Hadley and oncologist Robert Dorr, working alongside Victor Hruby's chemistry group — set out to synthesise a superpotent, metabolically stable analogue of alpha-melanocyte-stimulating hormone (α-MSH) with the express aim of inducing skin pigmentation without ultraviolet radiation exposure [PMID:16412534].

The scientific rationale was protective rather than cosmetic: the team hypothesised that a pharmacologically induced tanning response would provide photoprotection to fair-skinned individuals with high melanoma risk, offering a preventive strategy grounded in the skin's own pigmentary biology. Their early work with linear α-MSH analogues established that superpotency could be achieved through specific substitutions, most notably replacement of methionine at position four with norleucine (Nle) to eliminate oxidative lability, and exchange of the natural L-phenylalanine at position seven with its D-isomer to enhance receptor dwell time [PMID:16412534].

The critical advance that produced Melanotan II was cyclisation. By introducing a lactam bridge between aspartate and lysine residues, the research group locked the peptide backbone into a constrained conformation that strongly favoured binding to melanocortin receptors — yielding a molecule approximately one thousand times more potent than endogenous α-MSH in receptor binding assays [PMID:8637402]. This structural rigidity simultaneously conferred resistance to proteolytic degradation, extending the plasma half-life well beyond that of the native seven-amino-acid hormone. The compound entered a pilot Phase I clinical study in 1996, which confirmed the tanning effect in human volunteers — but also revealed the broad receptor engagement that would define its safety profile and ultimately redirect the field toward more selective analogues.

Mechanism of action — broad melanocortin agonism

Melanotan II is not a selective tool compound. Its cyclic, conformationally restricted structure confers high-affinity agonism at four of the five melanocortin receptor subtypes — MC1R, MC3R, MC4R, and MC5R — making it the broadest-acting melanocortin agonist used in research. Each receptor mediates a distinct biological programme, and understanding the receptor map is essential for interpreting both the compound's research utility and its safety liabilities.

MC1R — pigmentation. The melanocyte MC1R is the intended target for photoprotection research. Agonism at MC1R activates adenylyl cyclase via Gs coupling, raising intracellular cyclic AMP and activating the MITF transcription factor, which drives upregulation of tyrosinase and other enzymes in the eumelanin biosynthetic pathway [PMID:16412534]. The resulting shift from pheomelanin to eumelanin production produces the characteristic darkening response. Eumelanin is the photoprotective form of melanin; its accumulation in the epidermis provides meaningful UV absorption and is the mechanistic basis for the compound's investigation as a sunless tanning and photoprotection agent.

MC3R and MC4R — energy balance and arousal. Central nervous system melanocortin receptors mediate appetite regulation, energy expenditure, and sexual function. MC4R in the paraventricular nucleus and medial preoptic area is the principal driver of the spontaneous penile erections and increased sexual motivation observed in male rodent models and reported by human volunteers in the Arizona Phase I trial [PMID:8637402][PMID:35011]. MC3R engagement in hypothalamic circuits contributes to appetite suppression and autonomic effects. This simultaneous hypothalamic engagement is absent from the later, more selective compound Bremelanotide (PT-141), which was deliberately engineered to retain MC4R agonism while minimising MC1R-mediated pigmentation. Melanotan II, by contrast, activates both axes simultaneously and without selectivity.

MC5R — exocrine glands. MC5R is expressed in exocrine tissue including lacrimal, sebaceous, and sweat glands. Agonism at MC5R in preclinical models influences sebum production and glandular secretion, though this receptor's contribution to the overall pharmacological profile of Melanotan II in research settings is considered secondary to the MC1R and MC4R effects [PMID:16412534].

The consequence of this polypharmacology is that Melanotan II cannot be used as a pigmentation research tool without simultaneously engaging central arousal and appetite circuits. This is not a side-effect that can be titrated away — it is intrinsic to the molecule's receptor binding profile and is the defining reason why the clinical development path bifurcated, with afamelanotide (a linear, MC1R-preferring analogue) taking the photoprotection route and Bremelanotide taking the sexual dysfunction route.

Researched applications

Tanning and photoprotection research. The Arizona Phase I study enrolled ten healthy volunteers and demonstrated statistically significant increases in skin pigmentation following subcutaneous administration, as assessed by reflectance spectrophotometry [PMID:8637402]. The magnitude of tanning was clinically visible and occurred without deliberate UV exposure, validating the original hypothesis. However, the co-occurring adverse effects — in particular, the spontaneous erections and nausea — led the Arizona group and their commercial partners to conclude that a more selective compound was required for the photoprotection indication. Development ultimately focused on afamelanotide (Scenesse), the linear analogue that received European Medicines Agency approval in 2014 for erythropoietic protoporphyria and remains the only approved melanocortin agonist in clinical use [PMID:31225929]. Melanotan II was not advanced through formal regulatory development for pigmentation.

Sexual behaviour research. Wessells et al. published the most cited human study of Melanotan II's arousal effects, demonstrating dose-dependent increases in erectile events and sexual desire in men with psychogenic and organic erectile dysfunction [PMID:11035391]. Pfaus et al. conducted parallel investigations in female rodent models, reporting facilitation of sexual solicitation behaviours via MC4R agonism [PMID:15218105]. This body of work directly informed the development of Bremelanotide, which entered Phase III clinical trials for hypoactive sexual desire disorder in women and received FDA approval in 2019. From a research-trajectory perspective, Melanotan II served as the proof-of-concept compound that validated the melanocortin arousal axis, with Bremelanotide representing the clinically optimised successor.

Appetite suppression and energy expenditure. Melanocortin research in rodent obesity models documented that central MC3R and MC4R agonism by Melanotan II reduced food intake and increased energy expenditure, making it a pharmacological tool in the study of hypothalamic feeding circuits. This research has since been largely superseded by the development of highly selective MC4R agonists and, separately, GLP-1 receptor agonists for metabolic indications. Melanotan II is not considered a viable research tool for metabolic work given its off-target receptor engagement.

Dosing as reported in published studies

No human dosing regimen for Melanotan II has been established through completed, safety-validated clinical trials. The information below reflects what appeared in the limited published human research and is reported here strictly for scientific context — not as a guide for any form of human administration.

In the Arizona Phase I trial, volunteers received doses in the range of 0.01 mg/kg administered subcutaneously, which in a 70 kg individual corresponds to approximately 0.7 mg per administration [PMID:8637402]. Nausea was dose-limiting and emerged prominently at the higher end of the studied range. Researcher-community literature commonly references a loading protocol beginning at 0.25 mg subcutaneously to assess tolerability, advancing incrementally toward 0.5–1 mg, followed by a proposed maintenance interval of approximately 0.5 mg administered twice weekly — but these figures derive from informal community practice, not controlled clinical data, and carry no evidential weight regarding safety or efficacy. There is no validated dose-response relationship, no published pharmacokinetic modelling at human-relevant doses beyond the initial Phase I work, and no data on cumulative effects of repeated exposure. These gaps represent fundamental scientific unknowns, not conservatively established safe ranges.

Safety profile — highest-risk melanocortin compound on this site

Melanotan II carries the most substantive safety concerns of any melanocortin compound documented on this platform, and researchers and institutions considering handling it must give these full weight.

Flushing and nausea. The Phase I trial reported facial flushing and nausea in the majority of participants, with nausea dose-limiting at higher exposures [PMID:8637402]. These effects onset within minutes of administration and can persist for one to two hours. They reflect direct MC3R and MC4R-mediated autonomic and emetic pathway activation, not a formulation artifact.

Spontaneous erections and involuntary arousal. Penile erections occurring without sexual stimulation were documented in male volunteers in the Phase I and Wessells studies [PMID:8637402][PMID:11035391]. This effect is pharmacologically predictable from MC4R agonism and cannot be selectively suppressed without blocking the intended tanning effect. Analogous central arousal phenomena may occur in female subjects, though these are less visibly apparent. This property creates obvious ethical and practical complications in research settings and must be addressed in study design and ethics review documentation.

Hyperpigmentation of naevi and moles. MC1R agonism does not selectively target keratinocytes; melanocytes throughout the body, including those within benign naevi, respond to elevated cAMP signalling. Darkening of pre-existing moles — sometimes dramatically — has been reported in both the Phase I literature and case studies documented by dermatology services. This is not merely a cosmetic concern. Altered pigmentation of naevi can obscure clinical monitoring for melanoma transformation and may complicate dermatological assessment for months following exposure.

Melanoma family history — absolute contraindication in research protocols. Any individual or animal model with a history of melanocyte-derived malignancy, or a documented family history of melanoma, must be explicitly excluded from any research protocol involving Melanotan II. MC1R-driven MITF activation and accelerated melanocyte proliferation represent a credible theoretical mechanism for promoting malignant transformation in susceptible individuals. This contraindication is not a precautionary boilerplate — it reflects a mechanistically grounded concern that is taken seriously by dermatological pharmacologists working in this field.

Unknown long-term effects. No long-term safety data exist. The Phase I study was short-duration. Cumulative effects of repeated MC1R, MC3R, MC4R, and MC5R stimulation over weeks or months — including on mole biology, hypothalamic feedback, cardiovascular function, and melanocyte turnover — remain entirely uncharacterised.

UK regulatory status 2026

Melanotan II is an unapproved medicinal product. It holds no Marketing Authorisation from the Medicines and Healthcare products Regulatory Agency and no equivalent approval from the European Medicines Agency, the US Food and Drug Administration, or any comparable national authority. The Human Medicines Regulations 2012 prohibit its sale, supply, export, or administration to humans for any therapeutic or cosmetic purpose.

The MHRA has specifically identified Melanotan II as an enforcement priority. The agency's published guidance and enforcement activity has targeted websites and traders marketing the compound as a tanning peptide or injectable tanning product for human use, as this framing constitutes unlicensed medicinal product supply. MHRA enforcement activity in this category includes Border Force seizures, warning letters, and in some instances criminal prosecution. This enforcement profile is more active for Melanotan II than for most other research peptides documented on this site, reflecting the volume of grey-market consumer sales that have occurred in the UK.

In vitro laboratory research — handling within a controlled, accredited laboratory environment with no administration to humans or animals — falls outside the scope of the Human Medicines Regulations. Researchers conducting legitimate in vitro receptor binding, cell signalling, or melanocyte biology studies may handle Melanotan II as a research chemical subject to institutional governance, ethics approval, and documentation requirements. Acquisition should be from a verified research-grade supplier with full chain-of-custody documentation.

Reconstitution and storage

Melanotan II is supplied as a lyophilised white powder and should be reconstituted with bacteriostatic water (0.9% benzyl alcohol) to a working concentration of 1 mg/mL. Swirl gently to dissolve; do not vortex or shake, as mechanical agitation promotes peptide aggregation. Reconstituted solution stored at 2–8°C in a sealed, amber or foil-wrapped vial is considered stable for approximately 28 days. For extended storage, aliquot into single-use volumes prior to freezing at -20°C; thaw each aliquot once and do not refreeze. Repeated freeze-thaw cycles increase degradation and may introduce particulate matter. Lyophilised powder stored desiccated below 25°C in sealed, light-protected conditions is stable for the duration specified by the supplier, typically 24 months from manufacture.

Frequently asked research questions

How does Melanotan II differ from Bremelanotide (PT-141)? Bremelanotide was developed specifically to retain MC4R agonism for the sexual dysfunction indication while reducing MC1R-mediated pigmentation activity. Melanotan II engages MC1R, MC3R, MC4R, and MC5R with roughly comparable affinity; Bremelanotide was selected from a library of analogues because it showed relative MC1R sparing. The practical consequence is that Bremelanotide does not produce tanning or mole darkening at research doses, whereas Melanotan II produces both pigmentation and arousal effects simultaneously. For arousal-axis research, Bremelanotide represents the more selective and better-characterised modern tool compound [PMID:15218105].

How does Melanotan II differ from afamelanotide (Scenesse)? Afamelanotide is a linear α-MSH analogue with MC1R preference and a prolonged-release implant formulation; it is the only approved melanocortin agonist in clinical use, licensed for erythropoietic protoporphyria. Unlike Melanotan II's cyclic lactam structure, afamelanotide does not carry the same degree of MC4R agonism and does not produce spontaneous erections at clinically used doses [PMID:31225929]. Afamelanotide represents the outcome of the same University of Arizona research programme that produced Melanotan II, refined over 30 years for clinical viability.

Why is mole darkening considered a serious concern rather than just a cosmetic effect? Dermoscopic surveillance of naevi relies on stable baseline appearance. Pharmacological induction of MC1R-mediated melanocyte activity throughout the body systematically alters every pigmented lesion simultaneously, making it impossible to distinguish melanocortin-induced darkening from malignant change during the period of compound activity. This undermines clinical monitoring in exactly the patient population — fair-skinned, high UV-exposure risk — for whom dermatological surveillance is most important.

Is Melanotan II detectable in standard drug screening? Conventional immunoassay drug screens used in occupational or forensic settings do not routinely test for melanocortin peptides. Liquid chromatography-mass spectrometry panels used in research doping control can detect Melanotan II and related analogues. The World Anti-Doping Agency has included melanocortin agonists on the prohibited list under the peptide hormones and growth factors category.

Does Melanotan II cause permanent changes to skin pigmentation? The evidence from Phase I research suggests that pigmentation effects are substantially reversible after cessation of administration, with colour returning toward baseline over weeks to months as the accelerated melanocyte activity declines [PMID:8637402]. Whether moles that darken during administration fully return to their precise pre-treatment appearance, and on what timeline, has not been studied in a manner that permits a definitive answer.

---

Melanotan II appears in the following research stacks on this site: Melanotan II + Bremelanotide Tanning Stack.

Source research-grade Melanotan II

Melanotan II — Broad-Spectrum α-MSH Analogue is sold for laboratory and in vitro research use only. UK regulatory status: Unapproved globally. MHRA enforcement priority for sales presented as a tanning agent for human use. Research and laboratory use only — never sell as cosmetic, supplement, or for human administration..

Source on PeptideBarn.co.ukFull monograph on PeptideAuthority.co.uk

References

Peer-reviewed sources for the claims summarised above. Links open PubMed or the journal DOI.

1. Dorr RT, Lines R, Levine N, et al.. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences. 1996;58(20) :1777-1784 doi:10.1016/0024-3205(96)00160-9 · PMID: 8637402
2. Hadley ME, Dorr RT.. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4) :921-930 doi:10.1016/j.peptides.2005.01.029 · PMID: 16412534
3. Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P.. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences. 2004;101(27) :10201-10204 doi:10.1073/pnas.0400491101 · PMID: 15218105
4. Wessells H, Levine N, Hadley ME, Dorr R, Hruby V.. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. International Journal of Impotence Research. 2000;12(Suppl 4) :S74-79 doi:10.1038/sj.ijir.3900582 · PMID: 11035391
5. Hjuler KF, Lolle I, Clemmensen A, et al.. Photoprotection by Melanotan I (afamelanotide) — a narrative review. Journal of the European Academy of Dermatology and Venereology. 2019;33(11) :2000-2006 doi:10.1111/jdv.15765 · PMID: 31225929